365 related articles for article (PubMed ID: 28065582)
41. Neuraminidase 1-mediated desialylation of the mucin 1 ectodomain releases a decoy receptor that protects against
Lillehoj EP; Guang W; Hyun SW; Liu A; Hegerle N; Simon R; Cross AS; Ishida H; Luzina IG; Atamas SP; Goldblum SE
J Biol Chem; 2019 Jan; 294(2):662-678. PubMed ID: 30429216
[No Abstract] [Full Text] [Related]
42. Investigations on the efficacy of monovalent Pseudomonas aeruginosa vaccine for oral administration in Pseudomonas aeruginosa experimental infection.
Meitert E; Sima F; Savulian C; Petrovici M; Chersulick E; Costache G
Arch Roum Pathol Exp Microbiol; 1989; 48(3):237-51. PubMed ID: 2519634
[TBL] [Abstract][Full Text] [Related]
43. Induction of humoral immune response against Pseudomonas aeruginosa flagellin(1-161) using gold nanoparticles as an adjuvant.
Dakterzada F; Mohabati Mobarez A; Habibi Roudkenar M; Mohsenifar A
Vaccine; 2016 Mar; 34(12):1472-9. PubMed ID: 26868080
[TBL] [Abstract][Full Text] [Related]
44. An engineered bispecific DNA-encoded IgG antibody protects against Pseudomonas aeruginosa in a pneumonia challenge model.
Patel A; DiGiandomenico A; Keller AE; Smith TRF; Park DH; Ramos S; Schultheis K; Elliott STC; Mendoza J; Broderick KE; Wise MC; Yan J; Jiang J; Flingai S; Khan AS; Muthumani K; Humeau L; Cheng LI; Wachter-Rosati L; Stover CK; Sardesai NY; Weiner DB
Nat Commun; 2017 Sep; 8(1):637. PubMed ID: 28935938
[TBL] [Abstract][Full Text] [Related]
45. Anti-PcrV antibody strategies against virulent Pseudomonas aeruginosa.
Sawa T; Ito E; Nguyen VH; Haight M
Hum Vaccin Immunother; 2014; 10(10):2843-52. PubMed ID: 25483637
[TBL] [Abstract][Full Text] [Related]
46. Depletion of natural killer cells increases mice susceptibility in a Pseudomonas aeruginosa pneumonia model.
Broquet A; Roquilly A; Jacqueline C; Potel G; Caillon J; Asehnoune K
Crit Care Med; 2014 Jun; 42(6):e441-50. PubMed ID: 24732238
[TBL] [Abstract][Full Text] [Related]
47. IgG subclass responses to Pseudomonas aeruginosa a- and b-type flagellins in patients with cystic fibrosis: a prospective study.
Lagacé J; Péloquin L; Kermani P; Montie TC
J Med Microbiol; 1995 Oct; 43(4):270-6. PubMed ID: 7562988
[TBL] [Abstract][Full Text] [Related]
48. Roles of specific amino acids in the N terminus of Pseudomonas aeruginosa flagellin and of flagellin glycosylation in the innate immune response.
Verma A; Arora SK; Kuravi SK; Ramphal R
Infect Immun; 2005 Dec; 73(12):8237-46. PubMed ID: 16299320
[TBL] [Abstract][Full Text] [Related]
49. Pathophysiological changes induced by Pseudomonas aeruginosa infection are involved in MMP-12 and MMP-13 upregulation in human carcinoma epithelial cells and a pneumonia mouse model.
Park JW; Shin IS; Ha UH; Oh SR; Kim JH; Ahn KS
Infect Immun; 2015 Dec; 83(12):4791-9. PubMed ID: 26438797
[TBL] [Abstract][Full Text] [Related]
50. Polyclonal anti-whole cell IgY passive immunotherapy shields against P. aeruginosa-induced acute pneumonia and burn wound infections in murine models.
Ahmadi TS; Behrouz B; Mousavi Gargari SL
Sci Rep; 2024 Jan; 14(1):405. PubMed ID: 38172232
[TBL] [Abstract][Full Text] [Related]
51. Immunogenicity of a fusion protein containing PilQ and disulphide turn region of PilA from Pseudomonas aeruginosa in mice.
Gholami M; Chirani AS; Razavi S; Falak R; Irajian G
Lett Appl Microbiol; 2017 Nov; 65(5):439-445. PubMed ID: 28857243
[TBL] [Abstract][Full Text] [Related]
52. Human airway epithelial cells sense Pseudomonas aeruginosa infection via recognition of flagellin by Toll-like receptor 5.
Zhang Z; Louboutin JP; Weiner DJ; Goldberg JB; Wilson JM
Infect Immun; 2005 Nov; 73(11):7151-60. PubMed ID: 16239509
[TBL] [Abstract][Full Text] [Related]
53. Immunogenicity of Pseudomonas aeruginosa recombinant b-type fagellin as a vaccine candidate: Protective efficacy in a murine burn wound sepsis model.
Behrouz B; Mahdavi M; Amirmozafari N; Fatemi MJ; Irajian G; Bahroudi M; Hashemi FB
Burns; 2016 May; ():. PubMed ID: 27156804
[TBL] [Abstract][Full Text] [Related]
54. Vaccination promotes TH1-like inflammation and survival in chronic Pseudomonas aeruginosa pneumonia. A new prophylactic principle.
Johansen HK; Cryz SJ; Hougen HP; Moser C; Høiby N
Behring Inst Mitt; 1997 Feb; (98):269-73. PubMed ID: 9382750
[TBL] [Abstract][Full Text] [Related]
55. Immunological evaluation of an alginate-based conjugate as a vaccine candidate against Pseudomonas aeruginosa.
Farjah A; Owlia P; Siadat SD; Mousavi SF; Ardestani MS; Mohammadpour HK
APMIS; 2015 Feb; 123(2):175-83. PubMed ID: 25470757
[TBL] [Abstract][Full Text] [Related]
56. Thermal injury-induced non-specific resistance to fatal Pseudomonas aeruginosa burn-infection in mice.
Pinto M; Zehavi-Willner T
Jpn J Exp Med; 1989 Oct; 59(5):189-96. PubMed ID: 2559218
[TBL] [Abstract][Full Text] [Related]
57. Active immunization using exotoxin A confers protection against Pseudomonas aeruginosa infection in a mouse burn model.
Manafi A; Kohanteb J; Mehrabani D; Japoni A; Amini M; Naghmachi M; Zaghi AH; Khalili N
BMC Microbiol; 2009 Feb; 9():23. PubMed ID: 19183501
[TBL] [Abstract][Full Text] [Related]
58. Two Novel Bacteriophages Improve Survival in
Jeon J; Yong D
Appl Environ Microbiol; 2019 May; 85(9):. PubMed ID: 30824445
[TBL] [Abstract][Full Text] [Related]
59. Hypoxia modulates infection of epithelial cells by Pseudomonas aeruginosa.
Schaible B; McClean S; Selfridge A; Broquet A; Asehnoune K; Taylor CT; Schaffer K
PLoS One; 2013; 8(2):e56491. PubMed ID: 23418576
[TBL] [Abstract][Full Text] [Related]
60. Protective effects of affinity-purified antibody and truncated vaccines against Pseudomonas aeruginosa V-antigen in neutropenic mice.
Moriyama K; Wiener-Kronish JP; Sawa T
Microbiol Immunol; 2009 Nov; 53(11):587-94. PubMed ID: 19903258
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
